BARI, Alessia
 Distribuzione geografica
Salva come PNG Salva come JPEG
Continente #
NA - Nord America 11.559
EU - Europa 4.666
AS - Asia 4.531
SA - Sud America 695
Continente sconosciuto - Info sul continente non disponibili 181
AF - Africa 170
OC - Oceania 35
Totale 21.837
Salva come PNG Salva come JPEG
Nazione #
US - Stati Uniti d'America 11.329
GB - Regno Unito 1.797
SG - Singapore 1.335
CN - Cina 1.158
IT - Italia 852
HK - Hong Kong 538
BR - Brasile 511
VN - Vietnam 491
DE - Germania 427
SE - Svezia 357
FR - Francia 283
BD - Bangladesh 256
FI - Finlandia 204
RU - Federazione Russa 190
UA - Ucraina 184
TR - Turchia 165
CA - Canada 113
IN - India 104
KR - Corea 102
ID - Indonesia 75
BG - Bulgaria 72
AR - Argentina 61
MA - Marocco 56
MX - Messico 52
IQ - Iraq 43
ZA - Sudafrica 43
JP - Giappone 37
BE - Belgio 33
ES - Italia 33
PK - Pakistan 32
PL - Polonia 32
AU - Australia 31
EC - Ecuador 30
LT - Lituania 30
IE - Irlanda 29
NL - Olanda 28
AT - Austria 26
SA - Arabia Saudita 26
CO - Colombia 25
PH - Filippine 25
AE - Emirati Arabi Uniti 21
CL - Cile 20
CZ - Repubblica Ceca 20
UZ - Uzbekistan 17
KE - Kenya 14
IR - Iran 13
JM - Giamaica 13
JO - Giordania 13
MY - Malesia 13
CR - Costa Rica 12
VE - Venezuela 12
CH - Svizzera 11
PY - Paraguay 11
EG - Egitto 10
AZ - Azerbaigian 9
BO - Bolivia 9
PT - Portogallo 9
DZ - Algeria 7
GR - Grecia 7
KG - Kirghizistan 7
NO - Norvegia 7
PE - Perù 7
UY - Uruguay 7
BH - Bahrain 6
DO - Repubblica Dominicana 6
EU - Europa 6
IL - Israele 6
KZ - Kazakistan 6
NP - Nepal 6
RO - Romania 6
ET - Etiopia 5
HU - Ungheria 5
LB - Libano 5
NI - Nicaragua 5
RS - Serbia 5
SV - El Salvador 5
TZ - Tanzania 5
AL - Albania 4
BZ - Belize 4
GH - Ghana 4
NG - Nigeria 4
NZ - Nuova Zelanda 4
PA - Panama 4
PS - Palestinian Territory 4
TH - Thailandia 4
TN - Tunisia 4
CI - Costa d'Avorio 3
GP - Guadalupe 3
HN - Honduras 3
OM - Oman 3
SK - Slovacchia (Repubblica Slovacca) 3
SN - Senegal 3
CY - Cipro 2
DM - Dominica 2
GT - Guatemala 2
HR - Croazia 2
MT - Malta 2
PR - Porto Rico 2
QA - Qatar 2
TT - Trinidad e Tobago 2
Totale 21.631
Salva come PNG Salva come JPEG
Città #
Southend 1.448
Ashburn 1.131
Fairfield 1.059
Santa Clara 954
Singapore 846
Woodbridge 702
Hong Kong 528
Houston 510
Chandler 497
San Jose 497
Seattle 446
Wilmington 401
Cambridge 380
Ann Arbor 327
Jacksonville 316
Council Bluffs 292
Beijing 274
Dearborn 261
Hefei 252
Nyköping 246
Los Angeles 212
Chicago 207
London 192
Modena 183
New York 160
Ho Chi Minh City 155
Helsinki 132
Hanoi 111
San Diego 106
Shanghai 98
Seoul 97
The Dalles 97
Milan 96
Frankfurt am Main 95
Salt Lake City 82
Princeton 76
Moscow 70
Sofia 70
Buffalo 69
Columbus 64
Izmir 64
São Paulo 63
Eugene 61
Munich 60
Dallas 55
Jakarta 55
Lauterbourg 52
Casablanca 42
Bologna 37
Rome 37
Boardman 36
Phoenix 36
Bremen 35
Elk Grove Village 34
Redwood City 33
Fremont 31
Montreal 31
Toronto 29
Brussels 28
Da Nang 28
Tampa 28
Warsaw 28
Falls Church 27
Dublin 26
Miami 26
Orem 23
Tokyo 23
Johannesburg 22
Dong Ket 20
North Bergen 20
Atlanta 19
Sterling 19
Turku 19
Brooklyn 17
Denver 17
Dhaka 17
Nanjing 17
Norwalk 17
Rio de Janeiro 17
Chengdu 16
Des Moines 16
Lancaster 16
Baghdad 15
Guangzhou 15
Poplar 15
Guayaquil 14
Nuremberg 14
Philadelphia 14
Detroit 13
Mexico City 13
Nairobi 13
Paris 13
San Giuliano Milanese 13
Stockholm 13
Tashkent 13
Amsterdam 12
Boston 12
Buenos Aires 12
Mumbai 12
Newark 12
Totale 15.274
Salva come PNG Salva come JPEG
Nome #
Therapy-related myeloid neoplasm in non-hodgkin lymphoma survivors. 627
Absolute monocyte count and lymphocyte-monocyte ratio predict outcome in nodular sclerosis Hodgkin lymphoma: Evaluation based on data from 1450 patients 555
Absolute monocyte count at diagnosis could improve the prognostic role of early FDG-PET in classical Hodgkin lymphoma patients 534
Anthracydine-fludarabine-containing regimens with or without rituximab in the treatment of patients with advanced follicular lymphoma 502
Incidence, clinical characteristics and survival of malignant lymphomas: a population-based study from a cancer registry in northern Italy. 474
The undergraduate nursing student evaluation of clinical learning environment: an Italian survey [La valutazione dell'ambiente di apprendimento clinico da parte degli studenti del Corso di Laurea in Infermieristica: una indagine italiana] 469
A Multicenter Phase II Study of Twice-Weekly Bortezomib plus Rituximab in Patients with Relapsed Follicular Lymphoma: Long-Term Follow-Up 463
Monocytosis has adverse prognostic significance and impacts survival in patients with T-cell lymphomas 448
Clusterin enhances AKT2-mediated motility of normal and cancer prostate cells through a PTEN and PHLPP1 circuit 444
Empathic attitudes among nursing students: a preliminary study 422
Persistence of minimal residual disease in bone marrow predicts outcome in follicular lymphomas treated with a rituximab-intensive program 421
Secondary malignancies after treatment for indolent non-Hodgkin's lymphoma: A 16-year follow-up study 415
Second malignancies after treatment of diffuse large B-cell non-Hodgkin's lymphoma: a GISL cohort study 398
Bisphosphonate-Related Osteonecrosis of the Jaw (BRONJ) 389
Combination of low doses of Enzastaurin and Lenalidomide has synergistic activity in B-non-Hodgkin lymphoma cell lines 381
Activity of BKM120 and BEZ235 against lymphoma cells 377
Safety and efficacy of lenalidomide in combination with rituximab in recurrent indolent non-follicular lymphoma: Final results of a phase II study conducted by the Fondazione Italiana Linfomi 367
Defining the best cut-off value for lymphopenia in diffuse large B cell lymphoma treated with immuno-chemotherapy 366
Calcium-Carbonate Nanocapsules Improve the Efficacy of BEZ235 in Lymphoma a Cell Line: A Promising New Technology of Drug Delivery 357
Bendamustine, Low-dose dexamethasone, and lenalidomide (BdL) for the treatment of patients with relapsed/refractory multiple myeloma confirms very promising results in a phase I/II study 356
The histone deacetylase inhibitor romidepsin synergizes with lenalidomide and enhances tumor cell death in T-cell lymphoma cell lines 355
A concise review of lenalidomide therapy for follicular lymphoma 351
Neutrophil-lymphocyte ratio at diagnosis is an independent prognostic factor in patients with nodular sclerosis Hodgkin lymphoma: Results of a large multicenter study involving 990 patients 338
The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of Pet-guided treatments 334
Survival of multiple myeloma patients in the era of novel therapies confirms the improvement in patients younger than 75 years: a population-based analysis 324
Prognostic models for diffuse large B-cell lymphoma in the rituximab era: a never-ending story. 323
Dialysis-dependent renal failure at diagnosis continues to be associated with very poor outcome in multiple myeloma - response to Murphy et al 323
Phase II Study of Velcade (R) Plus Mabthera (R) In Relapsed Follicular Lymphomas. 321
The combination of bortezomib with enzastaurin or lenalidomide enhances cytotoxicity in follicular and mantle cell lymphoma cell lines 321
Anthracycline-Fludarabine Containing Regimens with or without Rituximab in the Treatment of Advanced Follicular Lymphoma Patients 319
Rituximab maintenance compared with observation after brief first-line R-FND chemoimmunotherapy with rituximab consolidation in patients age older than 60 years with advanced follicular lymphoma: A phase III randomized study by the fondazione Italiana linfomi 316
Risk for second malignancies in non-Hodgkin's lymphoma survivors: a meta-analysis 313
Radiation therapy improves treatment outcome in patients with diffuse large B-cell lymphoma 311
Risk of second primary malignancy in breast cancer survivors: A nested population-based case-control study 310
Rapid loss of response after withdrawal of treatment with azacitidine: A case series in patients with higher-risk myelodysplastic syndromes or chronic myelomonocytic leukemia 296
Rational combinations of enzastaurin with novel targeted agents for patients with B-cell non-Hodgkin's lymphoma 295
Incidence and outcome of Myelodysplastic Syndromes in province of Modena 293
Genomic profiling of enzastaurin-treated B cell lymphoma RL cells 292
A RANDOMIZED PHASE II STUDY (GISL - MM03 TRIAL) WITH ORAL MELPHALAN+ PREDNISONE (MP) VERSUS MELPHALAN, + PREDNISONE + THALIDOMIDE (MPT) FOR NEWLY DIAGNOSED ELDERLY PATIENTS WITH MULTIPLE MYELOMA 291
INCIDENCE AND SURVIVAL OF MYELOID MALIGNANCIES IN 1102 PATIENTS IN PROVINCE OF MODENA, NORTHERN ITALY 290
Introduction of rituximab in front-line and salvage therapies has improved outcome of advanced-stage follicular lymphoma patients 285
The potential of pralatrexate as a treatment of peripheral T-cell lymphoma 281
Monocyte count at diagnosis is a prognostic parameter in diffuse large B-cell lymphoma: a large multicenter study involving 1191 patients, in the pre and post rituximab era 274
Incidence and outcome of chronic myeloproliferative disorders: A population-based study from a cancer registry in northern Italy 273
: Late toxicity and quality of life (QOL) after treatment for Hodgkin disease (HD): A Gruppo Italiano Studio Linfomi (GISL) cohort study on 223 patients 273
Khorana score and histotype predict the incidence of early venous thromboembolism (VTE) in Non Hodgkin Lymphoma (NHL). A pooled data analysis of twelve clinical trials of Fondazione Italiana Linfomi (FIL) 266
End of induction [18F]FDG PET is prognostic for progression-free survival and overall survival in follicular lymphoma patients enrolled in the FOLL12 trial 265
Second Malignancy After Treatment for Non-Hodgkin Lymphoma: a Systematic Review and a Meta-Analysis of Population-Based and Cohort Studies 260
Secondary malignancies after treatment of aggressive non-Hodgkin lymphoma: A GISL cohort study on 1259 patients 257
SECOND MALIGNANCIES AFTER TREATMENT FOR INDOLENT LYMPHOMA: A 16 YEARS FOLLOW-UP STUDY 255
VALIDATION OF ABSOLUTE LYMPHOCYTE COUNT / REVISED IPI (ALC/R-IPI) SCORE MODEL, AS A PROGNOSTIC INDEX FOR DIFFUSE LARGE-B-CELL LYMPHOMA IN RITUXIMAB ERA 250
Prognostic roles of absolute monocyte and absolute lymphocyte counts in patients with advanced-stage follicular lymphoma in the rituximab era: an analysis from the FOLL05 trial of the Fondazione Italiana Linfomi 250
Is endoscopic ultrasound clinically useful for follow-up of gastric lymphoma? 249
Reduced intensity VEPEMB regimen compared with standard ABVD in elderly Hodgkin lymphoma patients: Results from a randomized trial on behalf of the Fondazione Italiana Linfomi (FIL) 236
NATURAL HISTORY OF CRYOGLOBULINEMIA FROM 2000 TO 2018 FROM THE LABORATORY POINT OF VIEW: AN ANALYSIS OF CRYOGLOBULIN CHARACTERISTICS IN A SINGLE CENTER. 232
Improving the international prognostic index score using peripheral blood counts: Results of a large multicenter study involving 520 patients with diffuse large B cell lymphoma 232
Introduction of Combined Chemotherapies Plus Rituximab (R) Has Improved Outcome of Previously Untreated and Relapsed Follicular Lymphoma (FL) Patients (pts).. 229
Impact of immunochemotherapy with R-bendamustine or R-CHOP for treatment naïve advanced-stage follicular lymphoma: A subset analysis of the FOLL12 trial by Fondazione Italiana Linfomi 200
Obinutuzumab and miniCHOP for unfit patients with diffuse large B-cell lymphoma. A phase II study by Fondazione Italiana Linfomi 194
Treatment of patients with recurrent follicular lymphoma with rituximab in combination with fludarabine and cyclophosphamide 191
Management of lymphoma survivor patients in Italy: an evaluation by Fondazione Italiana Linfomi 188
Khorana score and histotype predicts incidence of early venous thromboembolism in Non-Hodgkin lymphomas: A Pooled-Data analysis of 12 clinical trials of fondazione italiana linfomi (FIL) 186
Diagnosi di crioproteinemia: preziosa collaborazione tra laboratorio e clinica per la corretta gestione di una patologia rara 184
The prognostic role of end of treatment FDG-PET-CT in patients with diffuse large B cell lymphoma can be improved by considering it with absolute monocyte count at diagnosis 183
Rituximab in combination with chemotherapy has improved survival of patients with follicular lymphoma 182
Early progression beyond first-line chemoimmunotherapy in follicular lymphoma: Insights from a Fondazione Italiana Linfoma (FIL) study 152
Pazopanib-related secondary polycythemia in metastatic myxofibrosarcoma: A case report and review of the literature 143
Second Cancers in Classical Hodgkin Lymphoma and Diffuse Large B-Cell Lymphoma. A Systematic Review by the Fondazione Italiana Linfomi 123
Correction to: The classic prognostic factors in advanced Hodgkin’s lymphoma patients are losing their meaning at the time of pet-guided treatments (Annals of Hematology, (2020), 99, 2, (277-282), 10.1007/s00277-019-03893-7) 122
The impact of healthy lifestyles on late sequelae in classical hodgkin lymphoma and diffuse large b-cell lymphoma survivors. A systematic review by the fondazione italiana linfomi 121
Management of adverse events and supportive therapy in relapsed/refractory multiple myeloma 119
Management of multiple myeloma|Terapia del mieloma multiplo 101
Totale 21.837
Salva come PNG Salva come JPEG
Categoria #
all - tutte 79.014
article - articoli 0
book - libri 0
conference - conferenze 0
curatela - curatele 0
other - altro 0
patent - brevetti 0
selected - selezionate 0
volume - volumi 0
Totale 79.014
Salva come PNG Salva come JPEG


Totale Lug Ago Sett Ott Nov Dic Gen Feb Mar Apr Mag Giu
2021/20221.315 0 0 181 64 28 119 83 112 150 112 266 200
2022/20231.396 152 185 113 141 152 196 25 131 180 13 66 42
2023/20241.099 58 38 75 106 232 72 199 101 33 19 63 103
2024/20253.171 104 40 76 245 645 494 220 181 361 119 255 431
2025/20266.668 406 254 440 794 1.106 417 724 390 648 571 503 415
2026/2027748 165 531 52 0 0 0 0 0 0 0 0 0
Totale 21.837